These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21108519)

  • 21. Chronic hepatitis C virus management: 2000-2005 update.
    Hughes CA; Shafran SD
    Ann Pharmacother; 2006 Jan; 40(1):74-82. PubMed ID: 16368925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the evidence from clinical trials in chronic hepatitis C.
    Brown RS
    J Viral Hepat; 2006 May; 13 Suppl 1():15-25. PubMed ID: 16630043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Excitement grows for potential revolution in hepatitis C virus treatment.
    Opar A
    Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor.
    de Bruijne J; Bergmann JF; Weegink CJ; van Nieuwkerk CM; de Knegt RJ; Komoda Y; van de Wetering de Rooij JJ; van Vliet A; Jansen PL; Molenkamp R; Schinkel J; Reesink H; Janssen HL
    Antivir Ther; 2010; 15(5):765-73. PubMed ID: 20710058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribavirin in chronic hepatitis C: past and future.
    Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
    [No Abstract]   [Full Text] [Related]  

  • 26. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.
    Smith LS; Nelson M; Naik S; Woten J
    Ann Pharmacother; 2011 May; 45(5):639-48. PubMed ID: 21558488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hepatitis C: therapeutic perspectives].
    Trépo C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B297-302. PubMed ID: 12180304
    [No Abstract]   [Full Text] [Related]  

  • 28. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.
    Reesink HW; Zeuzem S; Weegink CJ; Forestier N; van Vliet A; van de Wetering de Rooij J; McNair L; Purdy S; Kauffman R; Alam J; Jansen PL
    Gastroenterology; 2006 Oct; 131(4):997-1002. PubMed ID: 17030169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Yatsuji H; Arase Y; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Iwasaki S; Kumada H
    J Clin Virol; 2010 Jan; 47(1):76-8. PubMed ID: 19857995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endpoints for clinical trials on treatment of hepatitis C.
    Kang H; Lok AS
    J Hepatol; 2006 Oct; 45(4):473-5. PubMed ID: 16901577
    [No Abstract]   [Full Text] [Related]  

  • 31. Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor.
    Kyvernitakis A; Jabbour E; Torres HA
    Clin Infect Dis; 2014 May; 58(9):1342-4. PubMed ID: 24501385
    [No Abstract]   [Full Text] [Related]  

  • 32. Futility of antiviral treatments for hepatitis C: an evolving concept entering the direct antiviral agents era.
    Bruno S; Mangia A
    Dig Liver Dis; 2013 May; 45(5):356-61. PubMed ID: 23102498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C.
    Lang L
    Gastroenterology; 2007 Jun; 132(7):2283-4. PubMed ID: 17570199
    [No Abstract]   [Full Text] [Related]  

  • 34. Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus.
    Kishi A; Hayashi N; Ohara K; Aoki K; Yamada I; Ikeda K; Kumada H
    J Am Acad Dermatol; 2014 Mar; 70(3):584-6. PubMed ID: 24528908
    [No Abstract]   [Full Text] [Related]  

  • 35. Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
    Muir AJ; McHutchison JG
    Hepatology; 2006 Dec; 44(6):1400-3. PubMed ID: 17133467
    [No Abstract]   [Full Text] [Related]  

  • 36. Future directions in therapy for chronic hepatitis C.
    Jensen DM; Ascione A
    Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome to interferon therapy in chronic hepatitis C: insights from mechanistic studies.
    Beard MR
    Antivir Ther; 2004 Oct; 9(5):637-9. PubMed ID: 15535401
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sarcoidosis and hepatitis C: clinical description of 11 cases.
    Faurie P; Broussolle C; Zoulim F; Trepo C; Sève P
    Eur J Gastroenterol Hepatol; 2010 Aug; 22(8):967-72. PubMed ID: 20216423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4.
    Sefcik RK; Bichoupan K; Martel-Laferrière V; Odin JA; Liu LU; Perumalswami P; Bansal M; Dieterich DT; Ahmad J; Schiano TD; Branch AD
    J Infect Dis; 2014 Dec; 210(11):1855-6. PubMed ID: 24970848
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.